Gene
NTRK2
NTRK2 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (4), Assay-provider ledger (26), Trial mentions (22), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention NTRK2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start and 3 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 9 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 21 of 11,460 | 0.18% |
| 2022 | 1 of 8,285 | 0.01% | 35 of 13,598 | 0.26% |
| 2021 | 3 of 8,692 | 0.03% | 43 of 15,045 | 0.29% |
| 2020 | 2 of 7,640 | 0.03% | 40 of 14,459 | 0.28% |
| 2019 | 1 of 7,300 | 0.01% | 34 of 12,159 | 0.28% |
| 2018 | 1 of 6,927 | 0.01% | 32 of 11,854 | 0.27% |
| 2017 | 3 of 6,558 | 0.05% | 36 of 11,595 | 0.31% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (4)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| TruSight Oncology Comprehensive | NTRK2 | Illumina, Inc. | Solid Tumors | 2024-08-21 |
| FoundationOne Liquid CDx | NTRK2 | Foundation Medicine, Inc. | Solid Tumors | 2022-12-22 |
| FoundationOne CDx | NTRK2 | Foundation Medicine, Inc. | Solid Tumors | 2022-06-07 |
| FoundationOne CDx | NTRK2 | Foundation Medicine, Inc. | Solid Tumors | 2020-10-23 |
Assay-provider ledger (26)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Horizon Diagnostics | Reagent supplier | Clinical validationAnalytical validation | 1 | October 17, 2025 |
| ROCHE DIAGNOSTICS | Context dependent | Clinical validationAnalytical validation | 1 | October 17, 2025 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 3 | October 17, 2025 |
| Foundation Medicine | Diagnostic provider | Clinical validationAnalytical validation | 3 | June 04, 2025 +1 undated |
| ROCHE | Context dependent | Clinical validationAnalytical validation | 1 | June 04, 2025 |
Showing 5 of 26 assay-provider companies.
Trial mentions (22)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05450822 | Trial biospecimen (AACT) |
| NCT03182257 | Trial eligibility (AACT) |
| NCT05769075 | Trial eligibility (AACT) |
| NCT03834961 | Trial eligibility (AACT) |
| NCT04631744 | Trial eligibility (AACT) |
Showing 5 of 22 trial mentions.
Target-disease associations (552)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 measurement | measurement | GWAS credible sets |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
| AKT2-related familial partial lipodystrophy | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 552 associations.
Vendor sourcing (76)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Canonical splice site: predicted to alter splicing and result in a ... | View ClinVar record SCV005904321.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV005875705.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1301A>G (p.Y434C) alteration is located in exon 14 (coding exon 11) of the NTRK2 gene. This alteration results from an A to G substitution at nucleotid... | View ClinVar record SCV001443930.4 |
| AnHeart Therapeutics Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Diagnosed with locally advanced or metastatic solid tumors harboring NTRK1, NTRK2, or NTRK3 fusion genes (anticipated to translate into fusion proteins... | View trial NCT04617054 |
| AnHeart Therapeutics Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Histologically or cytologically confirmed diagnosis of advanced solid tumors that have relapsed from or are refractory to standard treatment or for whi... | View trial NCT02279433 |
Showing 5 of 76 sourcing records.
Trial-cited literature (390)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Exploring the Connection Between BDNF/TrkB and AC/cAMP/PKA/CREB Signaling Pathways: Potential for Neuroprotection and Therapeutic Targets for Neurological Disorders. | Molecular neurobiology | 2025 | 40 |
| Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology | 2024 | 202 |
| TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury. | Life sciences | 2024 | 101 |
| Accelerated TMS - moving quickly into the future of depression treatment. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology | 2024 | 97 |
| Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice. | Journal of psychopharmacology (Oxford, England) | 2024 | 44 |
Showing 5 of 390 papers.
Protein variant mentions (7)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A11S | 1 | 2015 | PMID 25741868 |
| p.C600I | 1 | 2011 | PMID 21687501 |
| p.H671R | 1 | 2015 | PMID 25741868 |
| p.T794P | 1 | 2011 | PMID 21687501 |
| p.V437A | 1 | 2023 | PMID 37280397 |
Showing 5 of 7 variants.
Literature-extracted relations (43)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| AFATINIB | Chemical | negative_correlate |
Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma. | 2024 |
| Psilocybin | Chemical | associate |
Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice. | 2024 |
| Cholesterol | Chemical | associate |
TrkB transmembrane domain: bridging structural understanding with therapeutic strategy. | 2024 |
| Flavonoids | Chemical | positive_correlate |
Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury. | 2017 |
| Glutamic Acid | Chemical | associate |
BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. | 2005 |
Showing 5 of 43 relation assertions.
Organizations publishing (364)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 25 | 2008 to 2023 |
| Mass General Brigham | Hospital | 18 | 2012 to 2023 |
| Harvard Medical School | Academic | 17 | 2010 to 2022 |
| Memorial Sloan Kettering Cancer Center | Hospital | 11 | 2014 to 2022 |
| Stanford University | Academic | 10 | 2016 to 2023 |
Showing 5 of 364 organizations.
Where NTRK2 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
502 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects, actionable biomarkers, and human sample screening reference.